PMID- 12718806
OWN - NLM
STAT- MEDLINE
DCOM- 20030619
LR  - 20191107
IS  - 1201-9712 (Print)
IS  - 1201-9712 (Linking)
VI  - 7
IP  - 1
DP  - 2003 Mar
TI  - Preparation of a superantigen-adsorbing device and its superantigen removal 
      efficacies in vitro and in vivo.
PG  - 21-6
AB  - OBJECTIVE: A new superantigen-adsorbing device (SAAD) was developed, and its 
      characteristics and efficacy in septic animals were evaluated. METHODS: The SAAD 
      was prepared by stepwise chemical modification of a polystyrene-based composite 
      fiber reinforced with polypropylene. Adsorption affinities for several factors 
      and the biological effect of superantigen (SAg) removal were measured in vitro. 
      Also, superantigen-infused rabbits were treated with SAAD, and the efficacy was 
      evaluated in vivo. RESULTS: When the SAAD was evaluated for its ability to adsorb 
      SAg in human plasma (1 ng/mL each), the adsorption rates were 74%, 76% and 85% 
      for staphylococcal enterotoxins A, B and C, respectively, and 80% and 72% for 
      toxic shock syndrome toxin-1 (TSST-1) and streptococcal pyrogenic exotoxin A, 
      respectively. In addition, the SAAD showed some affinity towards other molecules, 
      such as streptococcal pyrogenic exotoxin B, beta2-microglobulin, and vancomycin. 
      Residual activities in whole blood samples containing TSST-1 (1 ng/mL) after 
      incubation with the SAAD were 125 pg/mL for tumor necrosis factor alpha 
      (TNF-alpha) production, and 359 pg/mL for interleukin-8 (IL-8) production (the 
      initial activities: 194 pg/mL for TNF-alpha production, and 1029 pg/mL for IL-8 
      production). When TSST-1/lipopolysaccharide (LPS)-infused rabbits were subjected 
      to extracorporeal blood purification with a SAAD column, 50% of the animals 
      survived for a 14-day period after the infusion. In contrast, all control animals 
      died within 3 days after the infusion. CONCLUSION: These results indicate that 
      the SAg-adsorbing device may be useful in treating SAg-related diseases.
FAU - Miwa, Keishi
AU  - Miwa K
AD  - Medical Devices Research Laboratory, Pioneering Research Laboratories, Toray 
      Industries Inc., 2-1 Sonoyama 3-chome, Otsu, Shiga 529-0842, Japan. 
      Keishi_Miwa@nts.toray.co.jp
FAU - Fukuyama, Mayumi
AU  - Fukuyama M
FAU - Ida, Nobuo
AU  - Ida N
FAU - Igarashi, Hideo
AU  - Igarashi H
FAU - Uchiyama, Takehiko
AU  - Uchiyama T
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Int J Infect Dis
JT  - International journal of infectious diseases : IJID : official publication of the 
      International Society for Infectious Diseases
JID - 9610933
RN  - 0 (Enterotoxins)
RN  - 0 (Exotoxins)
RN  - 0 (Polystyrenes)
RN  - 0 (Superantigens)
SB  - IM
MH  - Adsorption
MH  - Animals
MH  - Blood Component Removal/instrumentation/*methods
MH  - Enterotoxins/chemistry/isolation & purification
MH  - Exotoxins/chemistry/isolation & purification
MH  - Extracorporeal Circulation/instrumentation/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Polystyrenes/*chemistry
MH  - Rabbits
MH  - Sepsis/blood/therapy
MH  - Staphylococcus/metabolism
MH  - Streptococcus/metabolism
MH  - Superantigens/*chemistry/*isolation & purification
MH  - Time Factors
EDAT- 2003/04/30 05:00
MHDA- 2003/06/20 05:00
CRDT- 2003/04/30 05:00
PHST- 2003/04/30 05:00 [pubmed]
PHST- 2003/06/20 05:00 [medline]
PHST- 2003/04/30 05:00 [entrez]
AID - S1201971203900385 [pii]
AID - 10.1016/s1201-9712(03)90038-5 [doi]
PST - ppublish
SO  - Int J Infect Dis. 2003 Mar;7(1):21-6. doi: 10.1016/s1201-9712(03)90038-5.